Abstract
Background: HE4 may be a valuable early indicator of the recurrence of gynecologic cancers. Numerous studies have shown that high expression levels of serum HE4 correlate with ovarian and endometrial cancer recurrence. High HE4 levels may be an independent factor to predict these cancers’ poor prognosis.
Objective: This literature review investigates the relationship between serum HE4 levels and the recurrence of ovarian and endometrial cancer. Conclusion: HE4 displays malignant behavior by promoting cancer cells to skip from G1 phase to S phase, maintaining cell viability, encouraging cell proliferation, inhibiting cell apoptosis, and increasing resistance to drug treatments. Further studies are required to verify that elevated serum HE4 levels correlate with the recurrence of ovarian and endometrial cancer.Keywords: HE4, gynecologic cancers, ovarian cancers, endometrial cancers, cancer recurrence, prognosis.
Graphical Abstract
Current Drug Targets
Title:Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
Volume: 18 Issue: 10
Author(s): Jinping Li, Haibin Chen, John R. Curcuru, Sheena Patel, Taylor O. Johns, Dimple Patel, Hua Qian*Shi-wen Jiang*
Affiliation:
- Department of Obstetrics and Gynecology, the Taizhou People's Hospital, Taizhou 225300, Jiangsu,China
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China / Department of Biomedical Science, Mercer University School of Medicine, Savannah, Georgia 31404,United States
Keywords: HE4, gynecologic cancers, ovarian cancers, endometrial cancers, cancer recurrence, prognosis.
Abstract: Background: HE4 may be a valuable early indicator of the recurrence of gynecologic cancers. Numerous studies have shown that high expression levels of serum HE4 correlate with ovarian and endometrial cancer recurrence. High HE4 levels may be an independent factor to predict these cancers’ poor prognosis.
Objective: This literature review investigates the relationship between serum HE4 levels and the recurrence of ovarian and endometrial cancer. Conclusion: HE4 displays malignant behavior by promoting cancer cells to skip from G1 phase to S phase, maintaining cell viability, encouraging cell proliferation, inhibiting cell apoptosis, and increasing resistance to drug treatments. Further studies are required to verify that elevated serum HE4 levels correlate with the recurrence of ovarian and endometrial cancer.Export Options
About this article
Cite this article as:
Li Jinping, Chen Haibin, Curcuru R. John, Patel Sheena, Johns O. Taylor, Patel Dimple, Qian Hua*, Jiang Shi-wen *, Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170404154929
DOI https://dx.doi.org/10.2174/1389450118666170404154929 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity
Current Genomics Inhibition of Early Upstream Events in Prodromal Alzheimer’s Disease by Use of Targeted Antioxidants
Current Aging Science Targeting mTOR Signaling Pathway in Ovarian Cancer
Current Medicinal Chemistry Molecular Response to Hypericin-Induced Photodamage
Current Medicinal Chemistry Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Antioxidant, Anti-Inflammatory and Anticancer Activities of the Methanolic Extract of Thottea siliquosa: An <i>In Vitro</i> and <i>In Silico</i> Study
Recent Patents on Anti-Cancer Drug Discovery Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets Editorial [Hot Topic: Potential Application of Peptides in Tumor Targeting and Anticancer Therapeutics (Guest Editor: Jai Prakash)]
Current Pharmaceutical Biotechnology MicroRNAs for Diagnosis and Treatment of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Minimally Invasive Approach to Endometrial Cancer: Robotics and Laparoscopy
Current Women`s Health Reviews “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters The Potential Clinical Impact of Probiotic Treatment for the Prevention and/or Anti-Inflammatory Therapeutic Effect Against Radiation Induced Intestinal Mucositis. A Review
Recent Patents on Inflammation & Allergy Drug Discovery A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry Review of Estrone Sulfatase and its Inhibitors - An Important New Target Against Hormone Dependent Breast Cancer
Current Medicinal Chemistry Structural and Functional Diversity of Estrogen Receptor Ligands
Current Topics in Medicinal Chemistry The Involvement of Heat Shock Proteins and Related Molecules in the Resistance to Therapies in Breast and Gynecologic Cancer
Current Cancer Therapy Reviews The Genomics of Colorectal Cancer: State of the Art
Current Genomics